Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
Website:
http://elutia.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:28:39 GMTDividend
Analysts recommendations
Institutional Ownership
ELUT Latest News
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.
EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market
Elutia, Inc. (NASDAQ:ELUT) Q1 2024 Earnings Conference Call on May 9, 2024 at 4:30 PM ET with Company Representatives Matt Steinberg, Randy Mills, and Matthew Ferguson. Conference Call Participants include Frank Takkinen and Matthew Lambert from Lake Street Capital Markets and Cantor Fitzgerald. Operator: Good afternoon, and welcome to the Elutia First Quarter 2024 Financial Results Conference Call.
Elutia, Inc. (NASDAQ:ELUT ) Q4 2023 Results Conference Call March 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Randy Mills - President and Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Fourth Quarter and Full-Year 2023 Financial Results Call.
Elutia Inc. (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elutia, Inc. (NASDAQ:ELUT ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants David Carey - Finn Partners Randy Mills - President and Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Q3 2023 Financial Results Call.
Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.
What type of business is Elutia?
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
What sector is Elutia in?
Elutia is in the Healthcare sector
What industry is Elutia in?
Elutia is in the Medical Devices industry
What country is Elutia from?
Elutia is headquartered in United States
What is Elutia website?
https://elutia.com
Is Elutia in the S&P 500?
No, Elutia is not included in the S&P 500 index
Is Elutia in the NASDAQ 100?
No, Elutia is not included in the NASDAQ 100 index
Is Elutia in the Dow Jones?
No, Elutia is not included in the Dow Jones index
When does Elutia report earnings?
The next expected earnings date for Elutia is 14 August 2024